Culture Media and Blastocyst Development

April 23, 2018 updated by: Clinica Valle Giulia

Blastocyst Developmental Rate in Two Different Single Step Culture Media: a Sibling Oocyte Prospective Non-interventional Study

The aim of this non-interventional study is to compare the blastulation rate per fertilized oocyte in two different single step culture media commercially available (GEMS and Irvine culture media).

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

SUMMARY:

In ART procedures, blastocyst transfer can be considered the most physiological situation, as the embryo is placed in the uterine cavity at a stage most similar to that which occurs in nature. These potential benefits have induced more and more centres to move from cleavage stage to blastocyst stage embryo transfer all over the world (Maheshwari et al., 2016). Despite this, there are also some potential disadvantages. This approach decreases the total number of usable embryos (defined as those available for transfer or cryopreservation) (Glujovsky et al., 2016). Some concerns regarding the safety of this approach have also been raised. In particular, the extended duration of the in vitro culture may have long-term effect in the embryo development. In a recent meta-analysis, blastocyst stage transfer was in fact associated with increased risks of preterm birth (<37 weeks), very preterm birth (<32 weeks), large for gestational age and perinatal mortality, although the latter was only identified from one study. Conversely, blastocyst transfer was associated with a decrease in the risk of small for gestational age and vanishing twins, although this latter was reported by only one study (Martins et al., 2017).

Culture media plays a crucial role in this context. Two distinct approaches aimed at supporting embryo development to the blastocyst stage have been proposed: the "back to nature" sequential approach and the "let the embryo choose" single medium approach (Summers et al., 2003; Machtinger et al., 2012, Quinn 2012).

Sequential culture media system is designed to meet identified changing metabolic and nutritional requirements of the developing embryo from day 1 to day 5 (Gardner et al. 1996, 1997, 1998, 1999). With this approach, embryos are grown up to day 3 in a first medium and then, at the cleavage stage, are moved to a second one. The goal is to expose the embryos to stage-specific media, designed to reflect observed changes in concentrations of pyruvate, lactate, and glucose in the Fallopian tube versus the uterus (Gardner et al., 1996).

On the other hand, single culture media aim at allowing developing embryos to choose the nutrients they require, while at the same time minimizing stress from exposure to an abrupt change in their culture environment on day 3. Single media can be used with a medium change on day 3, or in a single-step uninterrupted culture, in which there is no medium refreshing on day 3 [Biggers et al., 2008]. Available data comparing the performance of single vs. sequential culture media suggest that both types of media seem to provide similar support to the developing embryo (Sfontouris et al., 2017).

Aim of the study and design

The aim of this non-interventional study is to compare the blastulation rate per fertilized oocyte in two different single step culture media commercially available (GEMS and Irvine culture media).

Oocyte collection

Consecutive egg collection will be performed (with inclusion of oocytes coming from woman not older than 42 years of age, presenting between 4 and 8 normal appearing MII oocytes and undergoing ICSI treatment with ejaculated sperm in the Centre for Reproductive Medicine GENERA in Rome). To exclude potential negative paternal effect on blastulation rate, all oocytes coming from couples with surgically extracted spermatozoa and very severe oligoastenoteratozoospermia (motile sperm count <500.000/ml after preparation) will be excluded. Oocytes coming from patients enrolled in PGD program for monogenic diseases or structural chromosomal abnormalities will be excluded too.

It is estimated, based centre experience, the study will last for 18 months. The informed consent is the GENERA standard format in ordinary use. The study will be approved by the Institutional Review Board of the Clinic.

Oocyte denudation, evaluation and injection All the procedures will be performed according to standard practice without any kind of intervention.

Just after the pick-up procedure, oocytes will be denuded from the cumulus oophorus by a brief exposure to 40 IU/ml hyaluronidase solution followed by mechanical removal of the corona radiata with the use of plastic pipettes of defined diameters in a controlled temperature environment. This procedure will be performed between 37 and 40 hours post hCG administration. Metaphase II (MII) oocytes will be then separated from the immature oocytes and evaluated at the stereomicroscope. Those with severe morphological abnormalities will be considered of lower quality (according to Rienzi et al., 2008) and will thus be excluded from comparison. All the MII oocyte will be placed in the same Petri Dish.

Using randomization tables, oocytes from each patient will be randomly split in two groups that will be independently inseminated and subsequently kept in 2 single step culture media, GEMS (GERI Medium) and Irvine (Continuous Single Culture Complete with HSA). Oocytes will be subjected to ICSI using previously described techniques and instrumentations (Rienzi et al., 1998). To be able to follow the developmental progression of individual oocyte, inseminated oocytes from each group will be cultured in separate dishes and each individual oocyte will be identified according to its position within the dish microwells. Embryo culture will last up to day 5 and will be performed in a time-lapse incubator (GERI, Genea) in hypoxic atmosphere containing 6%CO2 and 5%O2.

Embryo assessment

As per GENERA procedure, detailed analysis of various events during embryo development (syngamy, cleavages, compaction and blastulation) will be assessed using morphokinetic analysis. Various parameters will be assessed: time between the end of the ICSI procedure and syngamy, completion of cleavage to 2, 3, 4, 5 and 8 cells (T2, T3, T4, T5, T8, respectively); length of the first, second and third cell cycle (CC1, CC2, and CC3 respectively) and synchrony in the division from three to four and five to eight cells (S2 and S3, respectively). Standard blastocyst morphological assessment will be performed according to the criteria reported by Gardner and Schoolcraft (1999). In brief, the blastocysts will be evaluated according to the degree of expansion, quality of the inner cell mass (ICM) and of the trophectoderm cells (TE). The ICM is evaluated according to the number of cells, and the degree of compaction, while the TE is evaluated according to the number, dimension of the cells and the appearance of the epithelium (cohesive or loose). Morphokinetic parameters related to blastocyst formation will also be recorded and in particular: initiation of compaction, initiation of blastulation, and completion of blastulation (TSC, TSB, TB, respectively).

Statistical Considerations The primary study endpoint is the blastulation rate, computed as the percentage of fertilized eggs, cultured in either medium, that develop to the blastocyst stage in each half of the cohort. Since only women with between 4 and 8 retrieved oocytes will be eligible, and oocytes from each woman will be randomly split in 2 groups, assuming a fertilization rate of 80% the study population to be analysed will be composed by X*2 (where X is the number of enrolled women) groups of 2+ oocytes, half cultured in one medium and the other cultured in the second medium. The most obvious approach to the analysis of the resulting data is to consider it as a set of X (= number of women) 2x2 tables, where the quantity to be estimated is the odds ratio of blastulation of one medium relative to the other, to be analysed by means of the Mantel Haenszel procedure, with woman as the stratification factor (primary analysis). Assuming an overall blastulation rate of 34% a minimal relevant difference of 7% corresponds to an odds ratio of blastulation of 1.4. In order to detect with alfa=5% (2-sided) and power = 80% an odds ratio of 1.4, approximately 1200 (1182) oocytes need to be included (Hulley et al., 2013) split in 2 groups of equal sizes, that correspond approximately to 160 - 200 women (aprox. 6 oocytes/woman retrieved and considering a fertilization rate 80%).

In secondary exploratory analysis, a logistic model will be fitted to the data with blastulation as the dependent binary variable and woman as stratum, to assess the predictive value of various prognostic factors and the possible interactions between each of them and the culture medium.

Study Type

Observational

Enrollment (Anticipated)

160

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Italy
      • Roma, Italy, 00197
        • Recruiting
        • Clinica Valle Giulia
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 42 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

Assuming an overall blastulation rate of 34% a minimal relevant difference of 7% corresponds to an odds ratio of blastulation of 1.4. In order to detect with alfa=5% (2-sided) and power = 80% an odds ratio of 1.4, approximately 1200 (1182) oocytes need to be included (Hulley et al., 2013) split in 2 groups of equal sizes, that correspond approximately to 160 - 200 women (aprox. 6 oocytes/woman retrieved and considering a fertilization rate 80%).

Description

Inclusion Criteria:

-Woman not older than 42 years of age, presenting between 4 and 8 normal appearing MII oocytes and undergoing ICSI treatment with ejaculated sperm

Exclusion Criteria:

  • Men with surgically extracted spermatozoa and very severe oligoastenoteratozoospermia (motile sperm count <500.000/ml after preparation)
  • Oocytes coming from patients enrolled in PGT-M (preimplantation genetic testing for monogenic diseases) and PGT-SR (preimplantation genetic testing for structural chromosomal abnormalities) programs.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Other
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Group 1
Oocytes and embryos will be cultured in GEMS single step medium (in vitro culture in medium 1)
Other: In vitro culture in medium 1
Oocytes and embryos will be cultured in GEMS media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.
Group 2
Oocytes and embryos will be cultured in IRVINE single step medium (in vitro culture in medium 2)
Other: In vitro culture in medium 2
Oocytes will be cultured in IRVINE media (single step media) up to blastocyst stage.Standard IVF culture will be performed in a time lapse incubator. No drugs will be used.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blastulation rate
Time Frame: 7 days
The number of embryos reaching the blastocyst stage (day-5, day-6 or day-7 of preimplantation development) per fertilized oocyte (2PN)
7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Clinica Valle Giulia

Investigators

  • Principal Investigator: Laura Rienzi, MSc, Clinica Valle Giulia, G.en.e.r.a. centers for reproductive medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2018

Primary Completion (Anticipated)

April 1, 2019

Study Completion (Anticipated)

October 1, 2019

Study Registration Dates

First Submitted

April 6, 2018

First Submitted That Met QC Criteria

April 6, 2018

First Posted (Actual)

April 13, 2018

Study Record Updates

Last Update Posted (Actual)

April 24, 2018

Last Update Submitted That Met QC Criteria

April 23, 2018

Last Verified

April 1, 2018

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CVG11112017

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Embryo Development

Clinical Trials on In vitro culture in medium 1

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe